Eye drug trial for rare macular disease stops early – only 16 patients enrolled
NCT ID NCT03845049
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested aflibercept (Eylea) eye injections against placebo in 16 people with macular telangiectasia type 1, a rare condition that causes vision loss. The study aimed to see if aflibercept could reduce swelling in the macula. However, the trial was terminated early, so the results are limited and not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept (Eylea) eye injection
- What this could lead to
- If it works, this could point toward a treatment for vision loss from macular telangiectasia type 1.
- What could go wrong
- The trial was terminated early with only 16 participants, so results are very limited. It is unclear if aflibercept is better than placebo for this rare condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU dijon Bourgogne
Dijon, 21000, France